Introduction

Gene therapy involves instruments like viral vectors and plasmid DNA, that have developed as a favorable treatment option for various diseases such as viral, cancer and inherited disorders, especially those that currently lack a remedy. The use of therapeutic DNA (gene of interest) in cells involves gene therapy and genetically modified therapy. Application of vectors results in the gene transfer process in cells. Several viral and non viral plasmid DNAs for this purpose have, over the last few years, been standardized and optimized. The report provides analysis of global Viral Vector & Plasmid DNA Manufacturing market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year. According to Acumen Research and Consulting, the global Viral Vector & Plasmid DNA Manufacturing market is expected to grow at noteworthy CAGR around 21.4% throughout the forecast period and reach around US$ 1.8 billion by 2026.

Market Dynamics

The main drivers for the global production of viral vectors and plasmid DNA include an increase in the numbers of candidates for gene treatment and their rapid development over the many phases of clinical progression, vectors ' ability to effectively express therapeutic genes and non-pathogenicityof vectors. But the market growth is hampered by possible integrative mutagenesis and high costs for gene therapy. Technological advances to alleviate challenges arising from traditional vector production methods provide the producers of this industry with profitable opportunities.

Compared to recent decades, awareness of gene therapy is growing globally. The acceptance of gene therapy for severe disorders such as Alzheimer's disease, as opposed to less severe illnesses, such as the hyperactivity disorder, is high in an article published by Human Gene Therapy. Furthermore, gene therapy is becoming more acceptable and up to date information needs to be provided to the public and patients. In addition, opportunities for discussion on gene therapy research are a priority. During the prediction period, this is estimated as propelling the viral vector and plasmid DNA market. In addition, an increased awareness of gene therapy is driving growth in the manufacturing market for viral vectors and plasmid DNA for the predictable time. For example, the NHI launched a new initiative in November 2018 to increase gene therapy for approximately 20 million sickle cell diagnosed patients. Nevertheless, the adoption of gene treatment, thus impeding the market growth, is expected to restrict complications such as the risk of mutagenesis, safety and efficacy problems and stringent regulatory framework.

Industry Stance

The global production market for viral vectors and plasmid DNA is divided into types, uses, diseases, end-users, and region. In terms of type, lens viruses, adeno-associated viruses (AAV), plasmid DNA and others have been classified on the global market. The DNA segment dominates the value market for viral vector and plasmid DNA production. The segment is likely to be driven by increasing acceptance of advanced viral vector-based treatments. Also is likely to develop at a substantial CAGR during the prediction period, the adeno-associated virus (AAV) segment. This is mainly due in many other clinical trials around the world to the widespread use of AAV as an optional vector.

In terms of application, gene therapy, vaccinology and others have been classified on the world market. The Viral Vector & Plasmid DNA production market is dominated by gene therapy. The main attribution is that gene therapy products are increasingly accepted in the treatment of rare disorders around the globe and gene therapy products are available. During the forecast period, the segment of vaccinology will increase significantly in the CAGR. The expansion is due to increased research initiatives on vector-based viral vaccines.

In diseases, genetic disorders, cancer, infectious diseases and other diseases have been divided into global markets. The segment of cancer has value dominated the production of viral vectors & plasmid DNA. This is due primarily to aggressive research initiatives based on viral vector-based cancer products. In a significant CAGR during the forecast period, the GM disorder segment is expected to expand.

With regard to end users, the manufacturing market for viral vectors and plasmid DNA has been separated into biotech companies and research institutes. The biotech division, followed by the research institutes division, played a large role in the market in 2018. The biotech sector is expected to maintain its market share during the forecast period as the demand for large-scale production of viral vehicles and plasmid DNA for commercial uses increases.

Increasing incidence of genetic diseases, cancer, and infectious diseases

According to Cancer Research UK, 17 million new cancer cases occurred in 2018, with four of the world's most common cancer types representing some 43 percent of all new cases being breasts, lung, bowels and prostate cancres. According to estimates from the WHO, 10,000 human diseases, caused by changes in a single gene in the human DNA, are currently known to be monogenic. All genetic diseases have a global prevalence of about 10/1000 at the time of birth. In Canada, monogenic diseases are estimated to account for about 40% of the work of the pediatric practice of the hospital.

Increased prevalence of those conditions requires better treatments, which are projected to propel the production market of viral vector and plasmid DNA during the prediction period.

Regional Stance

In terms of region, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are divided into viral vector & plasmid DNA manufacturing markets. Due to the high acceptance in the US of viral vector products, the prevalence of cancer and monogenic disorders, the rich pipeline of product and technological progresses throughout the region, North America is dominating the global manufacturing market for viral vector & plasmid DNA. Due to increased research initiatives in countries like India and the availability of gene therapies based on viral vectors in countries like Japan and China, the market in Asia Pacific is projected to expand considerably during the projected period at a CAGR.

Market Segmentation

Global Viral Vector & Plasmid DNA Manufacturing Market, by Type

• Lentivirus
• Adenovirus
• Plasmid DNA
• Adeno-Associated Virus

Global Viral Vector & Plasmid DNA Manufacturing Market, by Application

• Gene Therapy
• Vaccinology

Global Viral Vector & Plasmid DNA Manufacturing Market, by Disease

• Infectious Disease
• Genetic Disorders
• Cancer

Global Viral Vector & Plasmid DNA Manufacturing Market, by End Use

• Research Institutes
• Biotech Companies

Global Viral Vector & Plasmid DNA Manufacturing Market, by Geography

• North America
• U.S.
• Canada
• Mexico

• Europe
• UK
• Germany
• France
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• Rest of Asia-Pacific
• Latin America
• Brazil
• Chile
• Rest of Latin America

• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• Rest of MEA

The market research study on “Viral Vector & Plasmid DNA Manufacturing Market (By Type: Lentivirus, Adenovirus, Plasmid DNA, Adeno-Associated Virus; By Application: Gene Therapy, Vaccinology; By Disease: Infectious Disease, Genetic Disorders, Cancer; By End Use: Research Institutes, Biotech Companies) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Viral Vector & Plasmid DNA Manufacturing market segments with market dynamics and their impact. The report also covers basic technology development policies.

The report offers an overview of the market and statistical diagrams to support the expected figures. Our analysts predict the market scope and future prospects in an insightful way. The Acumen Research and Consulting report contains a comprehensive analysis of the global market in Viral Vector & Plasmid DNA Manufacturing segmented by molecular type, test type and region. The report outlines numerous growth strategies implemented by companies as well as the latest market trends. The market share and current position of all leading players are discussed in detail. It analyzes players ' new revenue sources and highlights the different strategies.

Key Players & Strategies

The Viral Vector & Plasmid DNA Manufacturing market is consolidated with large number of manufacturers. Key players expand their product portfolios via mergers, acquisitions and partnerships, which is expected to increase the availability of products and therefore to boost the market.

The key players of the market are CobraBiologics, Novasep, Spark Therapeutics, Inc., FUJIFILM Diosynth Ltd, Cell and Gene Therapy Catapult, Kaneka Eurogentec, Inc. Merck KGaA, Lonza and UniQure N.V. and others.

TABLE OF CONTENT